The Individual and The Evidence: Treating Advanced Non-Small Cell Lung Cancer

Expiration: 7/9/2009
1.2 Contact Hours
Supported by sanofi-aventis, u.s.inc.

The goal of this webcast is to provide the participant with the means to challenge current thinking about the individualized treatment of the patient with non-small cell lung cancer including dose-intense therapy with an eye toward improved patient outcomes.

Through this comprehensive program you will be able to:

• Summarize patient characteristics that play a role in determining best treatment options for patients with advanced non-small cell lung cancer.
• Interpret and debate data defining therapeutic options for advanced non-small cell lung cancer.
• Devise individualized treatment recommendations for patients with advanced non-small cell lung cancer, with consideration to patient treatment goals, symptoms related to disease, and patient characteristics.
• Illustrate approaches to minimizing and managing treatment-related symptoms to improve patient outcomes.

Molecular Therapies Coming to a Bedside Near You

This presentation describes recently FDA approved targeted and biological therapies, including their indications, side effects and symptom management.  An overview of cancer biology sets the stage to discuss these agents and how they work. Targeted and biological therapies in later stages of clinical trials are also be discussed.

View Webcast | Take CNE Test

Clinical Breakthroughs in EGFR Inhibition: Applying the Science to Your Clinical Practice

2.1 Contact hours
Expiration: 10/01/2008
This webcast is supported by an educational grant from Amgen, Inc.

What are the hottest new clinical developments in targeted therapies?
This webcast takes a fascinating look at EGFR inhibition, including an illustrated explanation of cellular changes, a clinical review of promising new treatments, and a comprehensive discussion of side effects and their management. Participants will gain a clear understanding of how side effects correlate with treatment progression and with proven strategies to successfully manage the side effects of EGFR inhibitors.

CNE ID # 06-629-01

View Webcast | Take CNE test

The Cytokines and the B-Cell Malignancies: A New Spin on Maximizing Therapeutic Outcomes

1.70 Contact hours: through 12/31/06
1.4 starting 1/01/07
Expiration: 10/01/2008
This webcast is supported by an educational grant from Berlex Oncology, Inc.

Treatments for B-cell malignancies have shown great promise in overall survival and in improving quality of life. This case study-based webcast will examine the latest data in treating follicular lymphoma, large B-cell lymphoma, and chronic lymphocytic leukemia, including chemotherapy and targeted agents. Gain insight into the critical role that antibody-dependent cellular cytotoxicity plays in targeting malignant B-cells and what this means for your practice and your patients. Review how you have treated patients with Bcell malignancies and learn how others are managing similar cases.

CNE ID # 06-734-01

View Webcast | Take CNE test